Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer
New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not…